Introduction
Influenza A (H1N1 and H3N2) and B viruses are responsible for seasonal epidemics in the human population and cause substantial morbidity and mortality in high-risk groups such as elderly people. The antigenic properties of these viruses change regularly due to accumulation of mutations in the two major surface proteins, haemagglutinin (HA) and neuraminidase (NA), resulting in escape from pre-existing virus-neutralizing antibodies induced by previous infections or vaccinations (antigenic drift) [1] [2] [3] . In addition to seasonal influenza viruses, avian and swine influenza A viruses -for example, viruses of the A(H5N1) [4] , A(H5N6) [5] and A(H7N9) [6] subtype -cause occasional human infections. These zoonotic influenza viruses have the potential to cause pandemic outbreaks, as the human population is immunologically virtually naive.
Currently used inactivated vaccines against seasonal influenza viruses predominantly induce neutralizing antibodies against the globular head-domain of HA that neutralize homologous influenza viruses efficiently [3] . However, the breadth of reactivity of these antibodies is limited due to the high degree of variability in the headdomain of the HA glycoprotein between different influenza viruses, resulting in reduced vaccine efficacy in case of a vaccine mismatch with epidemic strains [3, [7] [8] [9] . Due to the antigenic drift of seasonal influenza viruses, vaccines need to be updated almost annually [10] . Furthermore, in case of a pandemic outbreak it is essential that a tailormade vaccine can be produced rapidly, which proved to be difficult during the pandemic of 2009. Thus, alternative cross-reactive correlates of protection induced by a 'universal' influenza vaccine with the capacity to provide intra-or intersubtypic immunity, such as virus-specific T cells, have gained renewed interest.
Virus-specific CD8 1 cytotoxic T cells predominantly recognize internal viral antigens, such as matrix (M1) and nucleoprotein (NP) , that are relatively conserved and contain epitopes shared by various subtypes of influenza virus. inefficiently by inactivated influenza vaccines (reviewed in [11] ) [12] [13] [14] . It has been shown that cross-reactive virusspecific CD8 1 cytotoxic T cells contribute to reduction of disease duration and severity after infection with a heterologous influenza virus [12, 15] . In addition, antibodies directed against the conserved stalk-domain of HA have been identified, which display cross-protective potential against infection with heterologous influenza viruses [16] [17] [18] [19] [20] . Thus, the development of vaccines that induce broadly protective HA stalk-specific antibodies and/or cellular immune responses against conserved proteins such as NP or M1 is highly desirable and is listed high on the research agenda (reviewed in [21] [22] [23] ).
Viral vaccine vectors, such as modified vaccinia virus Ankara (MVA), have been shown to efficiently induce antigen-specific humoral and cellular responses (reviewed in [24, 25] ). Recombinant (r)MVA vaccines have been tested extensively in various animal models and multiple clinical trials against different pathogens, including influenza virus, and has proved that the use of rMVA-based vaccines is safe [25] [26] [27] [28] . As it is relatively easy to insert genes encoding antigens of interest into the genome of MVA, recombinant (r)MVA-based vaccines can be rapidly produced [24, 25] . rMVA drives de-novo synthesis of one or multiple antigens of interest, leading to endogenous antigen processing and major histocompatibility complex (MHC) class I antigen presentation, which is important for the efficient induction of CD8
1 T cells (reviewed in [29] ). Humoral and cellular immunity could also be improved by the use of adjuvants in combination with for example virosomal, trivalent, split virion and inactivated influenza vaccines [30] [31] [32] [33] [34] [35] [36] [37] . Addition of Matrix-M TM adjuvant, made of saponins extracted from the tree Quillaja saponaria Molina [38] , to influenza vaccines enhances significantly humoral responses and the induction of virus-specific T cells in mice, ferrets and humans [31] [32] [33] [34] [35] [39] [40] [41] . Furthermore, Matrix-M TM adjuvant has been evaluated in three clinical Phase I studies using seasonal and pandemic (H5N1 and H7N9) influenza vaccines [32, 40, 42, 43] . All studies showed promising results with increased humoral and cellular responses along with good safety data.
Most adjuvanted influenza vaccine studies have focused upon the immune response towards HA (reviewed in [44] ). Additionally, a couple of studies have shown that adjuvanted recombinant influenza virus NP protein vaccines are able to induce T helper type 1 (Th1)-skewed CD4 1 T cell response and protect C57BL/6 mice from influenza A virus challenge [45, 46] . Here, we explore the effect of Matrix-M TM adjuvant on a recombinant influenza virus NP protein-based vaccine and compare it to rMVA-NP vaccines in BALB/c mice. Accordingly, the immunogenicity of unadjuvanted or Matrix-M TM adjuvanted wildtype NP (NPwt) protein-based vaccines and rMVA-based vaccines expressing NPwt or modified NP, optimized for proteasomal processing [47] 
Materials and methods

NPwt protein preparation
The NP was expressed in Escherichia coli BL21 as a Histagged maltose binding protein (MBP) fusion protein containing a DEVD sequence as cleavage site for murine (m)caspase3. Expression of the tagged MBP-NP fusion protein was induced by addition of 1 mM isopropyl b-D-1-thiogalactopyranoside (IPTG). After 4h induction at 288C the cells were harvested, lysed by sonication at 48C followed by centrifugation. The supernatant was loaded on Ni-Sepharose 6 FF (GE Healthcare, Amersham, UK) and proteins were eluted by applying an imidazole gradient. The 50 mM imidazole fractions containing the MBP-NP fusion protein were pooled and after incubation for 1 h at 378C in the presence of 0Á06 mg mcaspase3/mg fusion protein reloaded on Ni-IMAC resin. Analysis by sodium dodecyl sulphate-polyacrylamide gel electrophoresis/Coomassie Brilliant Blue (SDS-PAGE/CBB) staining and Western blot showed that more than 90% pure NP was recovered in the flow-through. NP was concentrated to 1 mg/ml and dialyzed against 25 mM HEPES, 300 mM NaCl pH 7Á5. The lipopolysaccharide (LPS) content (< 0Á25 EU/mg NP) was determined with EndoSafe-PTS test (Charles River, Franklin, MA, USA).
Matrix-M TM adjuvant
Novavax proprietary Matrix-M TM adjuvant is a saponinbased adjuvant consisting of two individually formed A. F. Altenburg et al.
40 nm-sized particles, each with a different and wellcharacterized saponin fraction (fraction-A and fraction-C, respectively). The Matrix-A and C particles are formed by formulating purified saponin from the tree Quillaja saponaria Molina with cholesterol and phospholipid [49] .
Generation of recombinant MVA
The rMVA constructs expressing NP under control of the early/late PsynII promotor were prepared as described recently [47] . In short, the respective (modified) NP nucleotide sequences (PR8-based, Accession number NC002019) were synthesized by Baseclear BV (Leiden, the Netherlands) and clonal rMVA viruses were prepared through transient mCherry-dependent plaque selection in chicken embryo fibroblasts (CEF) [47, 50] . To generate a final vaccine preparation, virus was propagated in CEF, purified by ultracentrifugation through 36% sucrose and reconstituted in 120 mM NaCl, 10 mM Tris-HCl pH 7Á4. rMVA-NP constructs were previously extensively characterized in vitro by sequencing, Western blot, confocal microscopy and radiolabelling experiments [47] .
Vaccination of BALB/c mice
Specified pathogen-free female BALB/c mice were purchased from Charles River Laboratories and were 8-10 weeks of age at the start of the experiment. Animals were housed in Makrolon type 3 cages, had access to food and water ad libitum and animal welfare was observed on a daily basis. All experiments were conducted in strict compliance with European guidelines (EU directive on animal testing 2010/63/EU) and the protocol was approved by an independent animal experimentation ethical review committee (Uppsala djurf€ ors€ oksetiska n€ amnd). Experiments were performed in two sets, the first set focused on the comparison of protein vaccines with MVA-based vaccines (Table 1 ) and the second set focused on the comparison of NPwt with modified NP expressed by MVA (Table 2) . BALB/c mice received two vaccinations (time interval of 4 weeks) with 10 8 plaque-forming units (PFU) rMVA, 10 lg NPwt protein or 1 or 10 mg NPwt protein adjuvanted with 5 or 10 mg Matrix-M TM adjuvant. All vaccines were administered subcutaneously in 100 ll at the base of the tail. Blood was sampled 21 days after the first vaccination and before mice were euthanized; 14 or 10 days after the second vaccination for the first and second set, respectively. Spleens were collected in phosphate-buffered saline (PBS) during necropsy and subsequently single-cells suspensions were prepared as described previously [34] .
Detection of NP-specific antibodies
Maxisorp microplates (Nunc, Rochester, NY, USA) were coated O/N at 48C with 50 ng/well NPwt protein (AmatsiQ-Biologicals, Ghent, Belgium) in 0Á05 M carbonate/ bicarbonate (Sigma Aldrich, Hamburg, Germany) buffer pH 9Á6. Plates were blocked for 1 h at room temperature using PBS with 0Á05% Tween-20 (PBST; Thermo Fisher Scientific, Fremont, CA, USA) pH 7Á2-7Á6 supplemented with 2% (W/ V) milk powder (Semper, Sweden). A three-or fivefold dilution series of the sera was prepared in blocking buffer starting at 1 : 30 and incubated on the coated plates for 1 h. Blocking buffer and anti-NP positive serum were used as a negative or positive control, respectively. Plates were washed with PBST and incubated with anti-IgG1 (Star 132P; AbD Serotec, Raleigh, NC, USA) or anti-IgG2a (Star 133P; AbD Serotec) horseradish peroxidase (HRP)-conjugated antibodies -indicative for a Th2 or Th1 response, respectively [51] -for 1 h. Subsequently, plates were washed with PBST and 100 ll 3,3 0 ,5,5 0 -tetramethylbenzidine (TMB) peroxidase substrate (Svanova Biotech, Uppsala, Sweden) was added. Reactions were stopped by adding 1Á8 M H 2 SO 4 and absorbance was measured subsequently at 450 nm using a SpectraMax Plus 384 Microplate Reader (Molecular Devices Corporation, Sunnyvale, CA, USA). Immunoglobulin (Ig)G1 and IgG2a anti-NP titres were calculated using a four-parameter logistic equation (Softmax software; Molecular Devices). The inflection point of the titration curve, i.e. half maximal effective concentration (EC 50 ) titre, was used for analysis. (Table 1) .
Vaccine immunogenicity was assessed by determining NP-specific antibody titres after one or two vaccinations (Fig. 1) . NP-specific antibody responses induced by the protein-based vaccines, with or without Matrix-M TM adjuvant, could not be detected after a single vaccination ( Fig. 1a and b) . In contrast, 21 days after the primary vaccination an NP-specific IgG2a response was detected after vaccination with rMVA-NPwt (Fig. 1b) . At 14 days after either protein or rMVA-NPwt booster vaccination NPspecific antibody responses were detected. Protein-based NPwt vaccines predominantly induced an IgG1 antibody response, whereas rMVA-NPwt induced both IgG1 and IgG2a NP-specific antibodies with a bias towards IgG2a (Fig. 1c,d ). The NP-specific IgG1 responses induced by protein-based vaccines and rMVA-NPwt were comparable (Fig. 1c) . Although not statistically significant, the immunogenicity of the protein-based NPwt vaccines was enhanced by the addition of Matrix-M TM adjuvant to the vaccine formulation, particularly for 10 lg NPwt 1 5 lg Matrix-M TM adjuvant (Fig. 1c,d) . Next, the vaccine-induced NP-specific T cell responses were evaluated. T cell activation was measured by stimulation of splenocytes obtained 14 days after the booster vaccination and subsequent detection of IL-2-, IFN-g-or IL-2/ IFN-g-producing NP-specific splenocytes. NP-specific T cell responses induced by protein-based vaccine formulations were enhanced significantly by Matrix-M TM adjuvant (Fig. 2) . Furthermore, Matrix-M TM adjuvanted NPwt protein vaccines induced more IL-2-producing T cells compared to rMVA-NPwt vaccination (Fig. 2a) . In contrast, no differences in IFN-g-or IL-2/IFN-g-producing cells between the Matrix-M TM adjuvanted NPwt protein vaccines and the rMVA-NPwt vaccine were observed (Fig.  2b,c) 
Modifications of NP do not enhance NP-specific CD8 1 T cell responses in BALB/c mice
In order to optimize the NP-specific CD8 1 T cell response, modifications were made to the NP protein that aimed at increasing protein processing and subsequent antigen presentation. Various NP mutant constructs were generated. First, the nuclear localization signal (NLS) of NP was mutated (NPmut) or deleted (NPDNLS) to retain the protein in the cytosol and increase the amount of protein available for proteasomal processing [47, 56, 57] . Secondly, NP was fused to ubiquitin (UbqNP), a small molecule marking proteins for proteasomal degradation [47, 58] . Previously, we have shown that these modified proteins could be expressed by rMVA and were immunogenic in C57BL/6 mice [47] . To determine whether the modified NP constructs are capable of inducing stronger NP-specific T cell responses than NPwt in BALB/c mice, animals were vaccinated twice with rMVA-NPwt, rMVA-NPmut, rMVA-NPDNLS or rMVA-UbqNP. Wild-type (wt)MVA was used as a negative empty-vector control. The rMVA-based vaccines were compared to vaccination with 10 lg NPwt protein formulated with 5 lg Matrix-M TM adjuvant (Table 2) . NP-specific antibody responses were determined using serum collected 21 and 10 days after the first and booster vaccination, respectively. Similar to the results obtained in MM 5 Matrix-M TM adjuvant. *P < 0Á0306; **P < 0Á0082; ***P 5 0Á0005. the initial experiment, vaccination with NPwt protein 1 Matrix-M TM adjuvant did not induce an NPspecific antibody response after a single vaccination. However, after two vaccinations both IgG1 and IgG2a NPspecific antibodies were detected with a bias towards IgG1 (Fig. 3a,c) . The IgG1 response of the adjuvanted protein vaccine was significantly higher than the response induced by the rMVA-NP constructs (Fig. 3c) . rMVA-NPwt induced NP-specific IgG2a antibodies after a single vaccination. Similar results were obtained for vaccination with rMVANPmut. In contrast, rMVA expressing NPDNLS (not statistically significant) or UbqNP seemed less immunogenic (Fig. 3b) . The differences in the induction of NP-specific IgG2a antibodies by the various rMVA-NP constructs was not detected after two vaccinations (Fig. 3d) . NP-specific antibody responses induced by the empty vector (wt)MVA were never observed (Fig. 3) .
Subsequently, NP-specific T cell responses induced by vaccination with 10 lg NPwt protein with 5 lg Matrix-M TM adjuvant or the respective rMVA-NP vaccines were addressed using two different assays. Using the FluoroSpot assay, the induction of specific T cells was demonstrated by detection of IL-2-, IFN-g-or IL-2/IFN-g-producing cells after splenocyte stimulation with an NP 147-155 peptide, representing a CD8 1 T cell epitope. wtMVA vaccination was used as a negative control and did not induce any NP 147-155 -specific T cell responses (Fig. 4) . NP 147-155 -specific IL-2-, IFN-g-or IL-2/IFN-g-producing T cells were detected for all rMVA-NP vaccine groups (Fig. 4a-c) . In general, the number of IL-2-, IFN-g-or IL-2/IFN-g-producing cells induced by the respective rMVA-NP vaccines were similar, although the number of virus-specific T cells induced by rMVA-NPDNLS seemed slightly elevated and by rMVA-UbqNP seemed slightly reduced compared to rMVANPwt (Fig. 4a-c) . Similar to the first experiment, NPwt protein 1 Matrix-M TM adjuvant vaccination induced similar numbers of IL-2-or IL-2 1 IFN-g-producing cells compared to rMVA-NPwt. In contrast, the numbers of IFN-gproducing cells after protein-based vaccination was significantly lower than after rMVA-NP vaccination (Fig. 4b) .
The vaccine-induced NP-specific T cell responses were also assessed using flow cytometry. IFN-g production after stimulation of splenocytes with NP 147-155 peptide was used to measure induction of NP-specific CD3 1 CD8 1 T cells (Fig. 4d) . A similar pattern to the FluoroSpot data was observed; all rMVA-NP vaccine groups induced NP-specific CD3
1
CD8
1 IFN-g-producing cells and, although not statistically significant, rMVA-NPDNLS induced slightly elevated and rMVA-UbqNP slightly reduced numbers of IFNg-producing T cells compared to rMVA-NPwt (Fig. 4e) . The use of NPwt protein, in combination with Matrix-M TM adjuvant, induced an NP 147-155 -specific CD8 1 T cell response inefficiently (Fig. 4e) . Thus, vaccination with rMVA-NP induced stronger NP-specific cytotoxic CD8
1 T cells than with adjuvanted recombinant NP preparation. However, MVA-driven expression of NP modified in order to increase its processing and presentation did not result in increased T cell responses in BALB/c mice. *P < 0Á0432; **P < 0Á0068; ***P < 0Á0009; ****P < 0Á0001.
Discussion
In this study, we investigated the immunogenicity of various influenza virus NP-based vaccines. Influenza virus NP is relatively conserved and an interesting target for the induction of (cross-)protective immune responses to influenza virus. Both NP-specific antibodies [59] [60] [61] and T cells [62] have been shown to contribute to protective immunity to influenza virus infections. Here, we compared the immunogenicity of unadjuvanted and Matrix-M TM adjuvanted protein and rMVA expressing NPwt or modified NP for their capacity to induce influenza virus NP-specific antibody and T cell responses in BALB/c mice.
Differential induction of NP-specific antibodies was observed after protein or MVA-based NP vaccination (Fig. 1) . As rMVA expresses full-length NP similar to the way it is expressed in influenza virus infection, it is likely that NP is exposed on the surface of rMVA-NP infected cells, leading potentially to more efficient induction of antibody responses after a single vaccination compared to vaccination with NPwt protein. The effect of this differential induction of antibody responses on a challenge infection was not addressed in this study.
As MVA is a replication-deficient virus capable of infecting cells it has intrinsic adjuvant capacities, such as activation of the innate immune system [63, 64] 
CD8
1 splenocytes per 10 6 events measured using flow cytometry. Mean for each group is indicated. MM 5 Matrix-M TM adjuvant. *P < 0Á0227; **P 5 0Á0073; ***P 5 0Á0005; ****P < 0Á0001. seemed lower compared to vaccination with Matrix-M TM adjuvanted NP (Fig. 2) . Of note, the concentration of protein or adjuvant used for vaccination did not make a significant difference in vaccine immunogenicity.
Immunogenicity of influenza virus nucleoprotein vaccines
In an attempt to optimize the NP-specific CD8 1 T cell response induced by vaccination, we previously generated rMVA constructs expressing modified NP. We have shown that deletion of the NLS or fusion of NP to ubiquitin increased degradation of NP and enhanced activation of NPspecific T cells in vitro. However, these modifications did not improve CD8
1 T cell responses in vivo or protection from a lethal challenge with influenza A virus in C57BL/6 mice [47] . We hypothesized that MVA-NPwt already induced an optimal T cell response in C57BL/6 (H-2Kb/Db) mice, because these mice mount a highly dominant CD8
1 T cells response to a single epitope located in NP (NP 366-374 ), which might mask any potential positive effects of the modifications. As this epitope is not recognized in in BALB/c mice (H-2Kd/ Db), we addressed if differences in immunogenicity of the various rMVA-NP constructs could be detected in this mouse model and compared it to NPwt 1 Matrix-M TM proteinbased vaccination.
The NP-specific IgG1 response induced by NPwt protein with Matrix-M TM adjuvant was significantly higher than the response induced by the rMVA-NP constructs (Fig. 3c) , similar to the trend in the first experiment (Fig. 1c) . Furthermore, NPDNLS and particularly UbqNP modifications resulted in lower IgG2a responses after a single vaccination, and lower IgG1 responses after two vaccinations compared to NPwt (Fig. 3b,c) . As these vaccines were designed to enhance NP degradation, the amount of antigen and the time window that these antigens are available for antibody recognition and induction of B cell responses is limited. Therefore, induction of lower antibody responses by these constructs is not surprising. However, after two immunizations comparable IgG2a responses were observed.
The induction of NP-specific CD8 1 T cells was detected after stimulation of splenocytes with the H-2Kd restricted CD8 1 T cell epitope NP 147-155 using the FluoroSpot assay and flow cytometry after intracellular IFN-g staining. IFNg responses measured by the FluoroSpot assay were significantly higher after vaccination with rMVA-NP constructs compared to NPwt 1 Matrix-M TM vaccination, whereas comparable low numbers of IL-2-and IFN-g/IL-2-producing cells were detected. Using flow cytometry, no NP 147-
-specific CD8
1 T cells were detected after vaccination with NPwt 1 Matrix-M TM adjuvant, indicating that the protein vaccine generates a mainly antigen-specific CD4 1 T cell response. This can be concluded from the experiment shown in Fig. 2 , in which splenocytes were stimulated with NP protein which predominantly activates CD4 1 T cells. Both in the FluoroSpot assay and using flow cytometry, rMVA-NPwt induced a NP-specific CD8
1 T cell response that could not be improved by modifying the NP protein (Fig. 4) . Notably, rMVA-UbqNP even induced slightly lower levels of NP-specific T cells compared to rMVA expressing NPwt, NPmut or NPDNLS (Fig. 4) , possibly in contrast to our hypothesis, the result of reduced availability of NP for direct antigen processing and presentation or crosspresentation [68] [69] [70] . We have shown previously in pulsechase experiments that the degradation kinetics vary for the different NP constructs; NPDNLS and particularly UbqNP had a higher degradation rate than NPwt and NPmut [47] . Therefore, the kinetics of the induction of the T cell response could differ between the different rMVA-NP constructs. In general, experiments in C57BL/6 and BALB/c mice show that NPwt is already optimally processed and presented, and that this cannot be improved by increasing the number of peptides available for presentation to T cells.
In conclusion, addition of the Matrix-M TM adjuvant to NPwt protein-based vaccines enhanced immunogenicity significantly, resulting in the induction of IgG2a as well as IgG1 antibody responses and increased T cell responses. Furthermore, rMVA-based NP vaccines seem to be capable of inducing a more diverse antibody (IgG1 and IgG2a) and cellular (IL-2, IFN-g, IL-2/IFN-g) response compared to protein-based NP vaccines, and only a single vaccination is enough to induce IgG2a antibody responses. The humoral and cellular immune response induced by rMVA expressing NPwt in BALB/c mice could not be enhanced further by increasing NP protein degradation. These results show that NP does not need any modifications to induce an optimal immune response.
